Please Wait.....
Report
Cell Analysis Market (End-user: Biotechnology & Pharmaceutical Companies, Academia, Cosmetic Industry, Contract Research Organizations, and Contract Development & Manufacturing Organizations) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
Market Report I 2023-08-22 I 166 Pages I Transparency Market Research
Cell Analysis Market - Scope of Report
TMR's report on the global cell analysis market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cell analysis market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cell analysis market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cell analysis market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cell analysis market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cell analysis market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cell analysis market.
The report delves into the competitive landscape of the global cell analysis market. Key players operating in the global cell analysis market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cell analysis market profiled in this report.
Key Questions Answered in Global Cell Analysis Market Report
- What is the sales/revenue generated by cell analysis across all regions during the forecast period?
- What are the opportunities in the global cell analysis market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2031?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
Cell Analysis Market - Research Objectives and Research Approach
The comprehensive report on the global cell analysis market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global cell analysis market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cell analysis market.
1. Preface
1.1. Market Definition and Scope
1.2. Key Research Objectives
2. Assumptions and Research Methodology
3. Market Overview
3.1. Overview
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Overview on R&D spending of major biotechnology and pharmaceutical companies by therapeutic area
3.3.1. Top 15 Origins of Pipeline Drugs
3.3.2. Biological versus non-biological drugs as a % of pipeline
3.3.3. Ongoing rise of gene and cell therapy
4. Global Cell Analysis Market Analysis and Forecast, by End-user
4.1. Introduction & Definition
4.2. Key Findings/Developments
4.3. Market Value Forecast, by End-user, 2017-2031
4.3.1. Biotechnology & Pharmaceutical Companies
4.3.2. Academia
4.3.3. Cosmetic Industry
4.3.4. Contract Research Organizations
4.3.5. Contract Development and Manufacturing Organizations
5. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Therapeutic Area
5.1. Introduction & Definition
5.2. Key Findings/Developments
5.3. Market Value Forecast, by Therapeutic Area, 2015-2031
5.3.1. Oncology & Immune-oncology
5.3.1.1. Small Molecules
5.3.1.2. Protein-based Therapeutics
5.3.1.3. Cell Therapy
5.3.1.4. Nucleic Acid-based Drugs
5.3.2. Cardiovascular & Metabolic Diseases
5.3.2.1. Small Molecules
5.3.2.2. Protein-based Therapeutics
5.3.2.3. Cell Therapy
5.3.2.4. Nucleic Acid-based Drugs
5.3.3. Immunology
5.3.3.1. Small Molecules
5.3.3.2. Protein-based Therapeutics
5.3.3.3. Cell Therapy
5.3.3.4. Nucleic Acid-based Drugs
5.3.4. Rare Diseases
5.3.4.1. Small Molecules
5.3.4.2. Protein-based Therapeutics
5.3.4.3. Cell Therapy
5.3.4.4. Nucleic Acid-based Drugs
5.3.5. Neurological Diseases
5.3.5.1. Small Molecules
5.3.5.2. Protein-based Therapeutics
5.3.5.3. Cell Therapy
5.3.5.4. Nucleic Acid-based Drugs
5.3.6. Others
5.3.6.1. Small Molecules
5.3.6.2. Protein-based Therapeutics
5.3.6.3. Cell Therapy
5.3.6.4. Nucleic Acid-based Drugs
6. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Technology
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Technology, 2017-2031
6.3.1. Flow Cytometry
6.3.2. Image-based Cytometry
6.3.3. Biochemical Assays
6.3.4. Mass Spectrometry
7. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Workplace
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Workplace, 2017-2031
7.3.1. Target Identification
7.3.2. Hit Generation & Lead Identification
7.3.3. Lead Optimization
7.3.4. In Vitro Preclinical Studies
7.3.5. In Vivo Preclinical Studies
7.3.6. Clinical Studies
8. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Country/Region
8.1. Key Findings
8.2. Market Value Forecast, by Country/Region, 2017-2031
8.2.1. U.S.
8.2.2. Europe
8.2.3. China
8.2.4. Rest of the World
9. U.S. Cell Analysis Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by End-user, 2017-2031
9.2.1. Biotechnology & Pharmaceutical Companies
9.2.2. Academia
9.2.3. Cosmetic Industry
9.2.4. Contract Research Organizations
9.2.5. Contract Development and Manufacturing Organizations
9.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
9.3.1. Oncology & Immune-oncology
9.3.1.1. Small Molecules
9.3.1.2. Protein-based Therapeutics
9.3.1.3. Cell Therapy
9.3.1.4. Nucleic Acid-based Drugs
9.3.2. Cardiovascular & Metabolic Diseases
9.3.2.1. Small Molecules
9.3.2.2. Protein-based Therapeutics
9.3.2.3. Cell Therapy
9.3.2.4. Nucleic Acid-based Drugs
9.3.3. Immunology
9.3.3.1. Small Molecules
9.3.3.2. Protein-based Therapeutics
9.3.3.3. Cell Therapy
9.3.3.4. Nucleic Acid-based Drugs
9.3.4. Rare Diseases
9.3.4.1. Small Molecules
9.3.4.2. Protein-based Therapeutics
9.3.4.3. Cell Therapy
9.3.4.4. Nucleic Acid-based Drugs
9.3.5. Neurological Diseases
9.3.5.1. Small Molecules
9.3.5.2. Protein-based Therapeutics
9.3.5.3. Cell Therapy
9.3.5.4. Nucleic Acid-based Drugs
9.3.6. Others
9.3.6.1. Small Molecules
9.3.6.2. Protein-based Therapeutics
9.3.6.3. Cell Therapy
9.3.6.4. Nucleic Acid-based Drugs
9.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
9.4.1. Flow Cytometry
9.4.2. Image-based Cytometry
9.4.3. Biochemical Assays
9.4.4. Mass Spectrometry
9.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
9.5.1. Target Identification
9.5.2. Hit Generation & Lead Identification
9.5.3. Lead Optimization
9.5.4. In Vitro Preclinical Studies
9.5.5. In Vivo Preclinical Studies
9.5.6. Clinical Studies
10. Europe Cell Analysis Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by End-user, 2017-2031
10.2.1. Biotechnology & Pharmaceutical Companies
10.2.2. Academia
10.2.3. Cosmetic Industry
10.2.4. Contract Research Organizations
10.2.5. Contract Development and Manufacturing Organizations
10.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
10.3.1. Oncology & Immune-oncology
10.3.1.1. Small Molecules
10.3.1.2. Protein-based Therapeutics
10.3.1.3. Cell Therapy
10.3.1.4. Nucleic Acid-based Drugs
10.3.2. Cardiovascular & Metabolic Diseases
10.3.2.1. Small Molecules
10.3.2.2. Protein-based Therapeutics
10.3.2.3. Cell Therapy
10.3.2.4. Nucleic Acid-based Drugs
10.3.3. Immunology
10.3.3.1. Small Molecules
10.3.3.2. Protein-based Therapeutics
10.3.3.3. Cell Therapy
10.3.3.4. Nucleic Acid-based Drugs
10.3.4. Rare Diseases
10.3.4.1. Small Molecules
10.3.4.2. Protein-based Therapeutics
10.3.4.3. Cell Therapy
10.3.4.4. Nucleic Acid-based Drugs
10.3.5. Neurological Diseases
10.3.5.1. Small Molecules
10.3.5.2. Protein-based Therapeutics
10.3.5.3. Cell Therapy
10.3.5.4. Nucleic Acid-based Drugs
10.3.6. Others
10.3.6.1. Small Molecules
10.3.6.2. Protein-based Therapeutics
10.3.6.3. Cell Therapy
10.3.6.4. Nucleic Acid-based Drugs
10.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
10.4.1. Flow Cytometry
10.4.2. Image-based Cytometry
10.4.3. Biochemical Assays
10.4.4. Mass Spectrometry
10.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
10.5.1. Target Identification
10.5.2. Hit Generation & Lead Identification
10.5.3. Lead Optimization
10.5.4. In Vitro Preclinical Studies
10.5.5. In Vivo Preclinical Studies
10.5.6. Clinical Studies
10.6. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Country/Sub-region, 2017-2031
10.6.1. EU5
10.6.2. U.K.
10.6.3. Switzerland
10.6.4. Rest of Europe
11. China Cell Analysis Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by End-user, 2017-2031
11.2.1. Biotechnology & Pharmaceutical Companies
11.2.2. Academia
11.2.3. Cosmetic Industry
11.2.4. Contract Research Organizations
11.2.5. Contract Development and Manufacturing Organizations
11.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
11.3.1. Oncology & Immune-oncology
11.3.1.1. Small Molecules
11.3.1.2. Protein-based Therapeutics
11.3.1.3. Cell Therapy
11.3.1.4. Nucleic Acid-based Drugs
11.3.2. Cardiovascular & Metabolic Diseases
11.3.2.1. Small Molecules
11.3.2.2. Protein-based Therapeutics
11.3.2.3. Cell Therapy
11.3.2.4. Nucleic Acid-based Drugs
11.3.3. Immunology
11.3.3.1. Small Molecules
11.3.3.2. Protein-based Therapeutics
11.3.3.3. Cell Therapy
11.3.3.4. Nucleic Acid-based Drugs
11.3.4. Rare Diseases
11.3.4.1. Small Molecules
11.3.4.2. Protein-based Therapeutics
11.3.4.3. Cell Therapy
11.3.4.4. Nucleic Acid-based Drugs
11.3.5. Neurological Diseases
11.3.5.1. Small Molecules
11.3.5.2. Protein-based Therapeutics
11.3.5.3. Cell Therapy
11.3.5.4. Nucleic Acid-based Drugs
11.3.6. Others
11.3.6.1. Small Molecules
11.3.6.2. Protein-based Therapeutics
11.3.6.3. Cell Therapy
11.3.6.4. Nucleic Acid-based Drugs
11.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
11.4.1. Flow Cytometry
11.4.2. Image-based Cytometry
11.4.3. Biochemical Assays
11.4.4. Mass Spectrometry
11.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
11.5.1. Target Identification
11.5.2. Hit Generation & Lead Identification
11.5.3. Lead Optimization
11.5.4. In Vitro Preclinical Studies
11.5.5. In Vivo Preclinical Studies
11.5.6. Clinical Studies
12. Rest of the World Cell Analysis Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by End-user, 2017-2031
12.2.1. Biotechnology & Pharmaceutical Companies
12.2.2. Academia
12.2.3. Cosmetic Industry
12.2.4. Contract Research Organizations
12.2.5. Contract Development and Manufacturing Organizations
12.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
12.3.1. Oncology & Immune-oncology
12.3.1.1. Small Molecules
12.3.1.2. Protein-based Therapeutics
12.3.1.3. Cell Therapy
12.3.1.4. Nucleic Acid-based Drugs
12.3.2. Cardiovascular & Metabolic Diseases
12.3.2.1. Small Molecules
12.3.2.2. Protein-based Therapeutics
12.3.2.3. Cell Therapy
12.3.2.4. Nucleic Acid-based Drugs
12.3.3. Immunology
12.3.3.1. Small Molecules
12.3.3.2. Protein-based Therapeutics
12.3.3.3. Cell Therapy
12.3.3.4. Nucleic Acid-based Drugs
12.3.4. Rare Diseases
12.3.4.1. Small Molecules
12.3.4.2. Protein-based Therapeutics
12.3.4.3. Cell Therapy
12.3.4.4. Nucleic Acid-based Drugs
12.3.5. Neurological Diseases
12.3.5.1. Small Molecules
12.3.5.2. Protein-based Therapeutics
12.3.5.3. Cell Therapy
12.3.5.4. Nucleic Acid-based Drugs
12.3.6. Others
12.3.6.1. Small Molecules
12.3.6.2. Protein-based Therapeutics
12.3.6.3. Cell Therapy
12.3.6.4. Nucleic Acid-based Drugs
12.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
12.4.1. Flow Cytometry
12.4.2. Image-based Cytometry
12.4.3. Biochemical Assays
12.4.4. Mass Spectrometry
12.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
12.5.1. Target Identification
12.5.2. Hit Generation & Lead Identification
12.5.3. Lead Optimization
12.5.4. In Vitro Preclinical Studies
12.5.5. In Vivo Preclinical Studies
12.5.6. Clinical Studies
List of Tables
Table 01: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (1/4)
Table 02: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (2/4)
Table 03: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (2/3)
Table 04: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (4/4)
Table 05: Top 15 Origins of Pipeline Drugs
Table 06: Global Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 07: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
Table 08: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
Table 09: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
Table 10: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
Table 11: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
Table 12: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
Table 13: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
Table 14: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 15: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
Table 16: Global Cell Analysis Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 17: U.S. Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 18: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
Table 19: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
Table 20: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
Table 21: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
Table 22: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
Table 23: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
Table 24: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
Table 25: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 26: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
Table 27: Europe Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 28: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
Table 29: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
Table 30: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
Table 31: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
Table 32: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
Table 33: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
Table 34: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
Table 35: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 36: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
Table 37: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 38: China Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 39: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
Table 40: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
Table 41: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
Table 42: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
Table 43: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
Table 44: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
Table 45: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
Table 46: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 47: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
Table 48: Rest of the World Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 49: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
Table 50: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
Table 51: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
Table 52: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
Table 53: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
Table 54: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
Table 55: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
Table 56: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 57: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
List of Figures
Figure 01: Major R&D spending therapeutic areas, by companies
Figure 02: Biological versus non-biological drugs as a % of pipeline
Figure 03: Ongoing rise of gene and cell therapy
Figure 04: Global Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
Figure 05: Global Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
Figure 06: Global Cell Analysis Market (US$ Mn), by Biotechnology & Pharmaceutical Companies, 2017-2031
Figure 07: Global Cell Analysis Market (US$ Mn), by Academia, 2017-2031
Figure 08: Global Cell Analysis Market (US$ Mn), by Cosmetic Industry, 2017-2031
Figure 09: Global Cell Analysis Market (US$ Mn), by Contract Research Organizations, 2017-2031
Figure 10: Global Cell Analysis Market (US$ Mn), by Contract Development and Manufacturing Organizations, 2017-2031
Figure 11: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 12: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
Figure 13: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Oncology & Immune-oncology, 2017-2031
Figure 14: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Cardiovascular & Metabolic Diseases, 2017-2031
Figure 15: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Immunology, 2017-2031
Figure 16: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Rare Diseases, 2017-2031
Figure 17: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Neurological Diseases, 2017-2031
Figure 18: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Others, 2017-2031
Figure 19: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
Figure 20: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
Figure 21: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Flow Cytometry, 2017-2031
Figure 22: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Image-based Cytometry/Microscopy, 2017-2031
Figure 23: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Biochemical Assays, 2017-2031
Figure 24: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Mass Spectrometry, 2017-2031
Figure 25: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Workplace, 2022 and 2031
Figure 26: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
Figure 27: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Target Identification, 2017-2031
Figure 28: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Hit Generation & Lead Identification, 2017-2031
Figure 29: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Lead Optimization, 2017-2031
Figure 30: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by In Vitro Preclinical Studies, 2017-2031
Figure 31: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by In Vivo Preclinical Studies, 2017-2031
Figure 32: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Clinical Studies, 2017-2031
Figure 33: Global Cell Analysis Market Value Share Analysis, by Region, 2022 and 2031
Figure 34: Global Cell Analysis Market Attractiveness Analysis, by Region, 2023-2031
Figure 35: U.S. Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
Figure 36: U.S. Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
Figure 37: U.S. Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
Figure 38: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 39: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
Figure 40: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
Figure 41: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
Figure 42: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
Figure 43: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
Figure 44: Europe Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
Figure 45: Europe Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
Figure 46: Europe Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
Figure 47: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 48: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
Figure 49: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
Figure 50: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
Figure 51: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
Figure 52: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
Figure 53: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 54: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 55: China Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
Figure 56: China Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
Figure 57: China Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
Figure 58: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 59: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
Figure 60: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
Figure 61: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
Figure 62: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
Figure 63: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
Figure 64: Rest of the World Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
Figure 65: Rest of the World Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
Figure 66: Rest of the World Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
Figure 67: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 68: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
Figure 69: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
Figure 70: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
Figure 71: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
Figure 72: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security